GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...
GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...
In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went ...
Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...
BDCDA alerts trade fraternity about theft of Lantus SoloStar of Sanofi India: Nandita Vijayasimha, Bengaluru Thursday, March 5, 2026, 08:00 Hrs [IST] The Bangalore District Chemis ...
Based on the DCGI alert on advisory has been issued to doctors and Healthcare professionals. "Doctors and healthcare professionals carefully prescribe and educate patients on reporting any ADRs.
The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results